Longer-term efficacy and safety of zodasiran in patients with mixed hyperlipidaemia
Authors' conclusion
Zodasiran produced sustained reductions in triglycerides and atherogenic lipoproteins over 30 months and was well tolerated
Study context
- Population
- Adults with mixed hyperlipidaemia (fasting TG 1.7–5.6 mmol/L and LDL-C ≥ 1.8 mmol/L or non-HDL-C ≥ 2.59 mmol/L) who completed 9 months of randomised treatment with placebo or zodasiran82% of 191 completers
- Participants
- 156 adults
- Primary endpoint
- % change in median TG from baseline (randomised double-blind study)
- Follow-up
- Month 6
Methodological detailsPhase 2b parent trial
- Phase 2b parent trial
Primary result
As reported in the abstract
Median TG, % change from baseline (open-label extension (OLE)) · Month 21
Median TG reduction by Month 21
−55%
95% CI 64, 43
Further findings
Remnant cholesterol, % change · Month 21
- Remnant cholesterol reduction by Month 21
- −57% (SD: 32)
LDL-C, % change · Month 21
- LDL-C reduction by Month 21
- −5% (SD: 40)
ApoB, % change · Month 21
- ApoB reduction by Month 21
- −13% (SD: 21)
Safety
| Outcome | Values |
|---|---|
| Discontinuation due to adverse events · 24 months | Zodasiran 3.2% |
Injection site reactions
- Injection site reactions were mild; generally well tolerated
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Longer-term efficacy and safety of zodasiran in patients with mixed hyperlipidaemia. Eur J Prev Cardiol. Published 24 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →